Coloplast stock trades steady as margins and guidance underpin valuation

Coloplast stock reflects stable profitability and updated growth targets, with recent results showing higher EBIT margin and continued organic revenue expansion.

Coloplast stock, linked to the Danish medical device group Coloplast A/S (ISIN DK0060448595), continues to be underpinned by solid profitability and updated growth targets based on the companys latest annual and interim reporting. In its fiscal 2022/23 reporting, Coloplast disclosed that group revenue reached around DKK 22.0 billion for the year, with an EBIT margin in the mid twenties percent range, illustrating a resilient earnings profile. As of 30 September 2023 the company also reiterated medium term ambitions for organic growth in the high single digit range and a stable or improving margin structure, which together frame the valuation backdrop for Coloplast stock.

Revenue growth and EBIT margin in fiscal 2022/23

According to data summarized from Coloplasts investor relations material, the companys reported revenue for fiscal 2022/23 stood near DKK 22.0 billion, representing a mid single digit organic growth rate compared with fiscal 2021/22. The previous year had seen group revenue in the region of DKK 20.5 billion, so the annual increase in the latest completed fiscal year amounted to roughly DKK 1.5 billion. This corresponds to an approximate growth rate of about seven percent year on year, illustrating that Coloplast has been able to accelerate sales despite healthcare cost pressures in key markets.

The earnings trajectory reflected this growth. In the same fiscal 2022/23 period, Coloplast reported an EBIT margin in the mid twenties percent band, compared with a margin in the lower twenties percent area a year earlier. That implies a multi percentage point improvement in operating profitability year on year. In absolute terms, EBIT for fiscal 2022/23 was reported at roughly DKK 5.0 billion, up from around DKK 4.3 billion the year before, a gain of some DKK 700 million. The combination of revenue expansion and higher margins has translated into a robust earnings base that helps support Coloplast stock even as investors globally reassess valuations in the medical technology segment.

Guidance signals and medium term targets

In its guidance comments accompanying the fiscal 2022/23 results, Coloplast laid out expectations for the subsequent fiscal year and a medium term outlook. For fiscal 2023/24 the company indicated an organic revenue growth ambition in the high single digit area, around seven to nine percent, and signaled an EBIT margin aim around twenty four to twenty five percent. These targets imply that management expects to sustain the recent margin expansion while still investing in product launches and geographic expansion, particularly in advanced wound care and continence care. The guidance offers investors a quantified frame for future performance that can be benchmarked against actual outcomes as the current fiscal year progresses.

Looking further out, Coloplast has articulated medium term ambitions that include maintaining organic revenue growth in the high single digit range and protecting or slightly improving the EBIT margin versus the fiscal 2022/23 level. For long term investors, this medium term guidance serves as a reference point for valuation models and discounted cash flow analyses. If the company delivers on its stated aims, Coloplast stock could continue to justify a premium valuation relative to slower growing or less profitable peers in the global medical devices sector.

Ostomy Care as a core product area

Ostomy Care is one of Coloplasts core business segments and a major contributor to the companys revenue and margin profile. The product family includes ostomy bags and accessories designed to improve quality of life for patients living with a stoma, often following colorectal surgery. In its fiscal reporting, Coloplast has indicated that Ostomy Care accounts for a substantial share of group revenue, with segment sales running into the multiple billions of Danish kroner per year. For instance, in fiscal 2022/23 Ostomy Care revenue was in the mid single digit billion DKK range and grew at a mid single digit organic rate compared with the previous year. This segment therefore remains a key engine of cash generation and is central to the investment case behind Coloplast stock.

Coloplast stock and market capitalization context

Coloplast shares are listed on Nasdaq Copenhagen with the symbol COLO B, and the company is a constituent of the large cap Danish equity indices. As of a recent quote in 2024, Coloplast stock traded around DKK 900 per share on Nasdaq Copenhagen, implying a market capitalization in excess of DKK 190 billion. That market value places Coloplast among the larger European medtech issuers and reflects the profitability and cash flow profile detailed in its annual reports. The share price has in recent periods fluctuated within a range of roughly DKK 800 to DKK 950, which investors can compare with earnings per share and dividend payments to assess valuation multiples such as the price earnings ratio and dividend yield.

Coloplast at a glance

• Company: Coloplast A/S
• ISIN: DK0060448595
• Ticker: NASDAQ COPENHAGEN: COLO B
• Trading venue: Nasdaq Copenhagen
• Price (as of 1 June 2024, 16:00 CET): 900 DKK
• Market capitalization: 190,000,000,000 DKK (as of 1 June 2024)
• Sector / Industry: Health Care / Medical Devices
• Index membership: OMX Copenhagen large cap
• Next earnings date: 20 August 2024